This mechanism is most likely responsible for the mucolytic effects of the drug, but may also explain the reported activity in Gaucher and Parkinson's disease.
The underlying process is likely to be responsible for the drug's mucolytic properties, although it could also explain the observed efficacy in Gaucher and Parkinson's disease.